Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
about
Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience.Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.BRCA1 pathway function in basal-like breast cancer cells.Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damageNucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancerPredictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.Current approaches to the management of Her2-negative metastatic breast cancer.Association of Tartrate-Resistant Acid Phosphatase-Expressed Macrophages and Metastatic Breast Cancer Progression.The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancerEribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Platinum-based compounds for the treatment of metastatic breast cancer.Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Assessing the role of platinum agents in aggressive breast cancers.PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
P2860
Q33393452-F3051C59-E3D1-4B64-B017-4E29039AD31DQ33393809-E6D10CAC-ED9C-4E8D-BA93-AD8A5AC84128Q33403234-8616B6E1-184F-4392-AAED-8C637A62606EQ33415281-03280E8F-177E-47EF-A3A9-AFC6A251983AQ34297981-62C99EDD-DA8B-483A-BD1B-B20294A9AC71Q34342840-AE1F5CBB-00DA-485A-8455-69B6E98607ECQ34410934-32C118B9-4569-4438-81ED-1BE9A45B1E5BQ34686858-78213A05-3C97-4D4E-944C-83A80A76F943Q34746035-0A78219E-FFA8-4CA8-9753-5B182068C1B5Q36245461-2829AC85-CF1A-4EF2-BC33-7F3A083F346FQ36359105-26EB244B-8653-4B7E-BE77-425E1CCCDDB8Q36763291-941BA1C3-F7BE-4B18-B973-A34B9C1A2173Q37356090-1630E31E-D21A-44FA-BE56-4CE2B49EE91EQ37687072-9E0F5D86-5B14-4162-B4C0-8DA8382209E8Q37876401-DF46E7F9-FEA3-45F6-B167-6814361891EEQ37976172-455F382D-639A-45B5-8BD1-0A3DB4237A03Q37994654-DE96272A-A358-4AAD-83A9-91536A41E8ADQ38276429-DCF85532-FEB4-452F-B460-F05115C436ADQ38349378-E4768121-12C0-4E96-A4C9-0D88A398FCB6Q38393692-AD5BF115-6A7C-46FB-B32F-37F7182D2F32Q39428059-0293F906-5738-4D47-8099-F01473F8C82AQ42706074-D982A4B8-1924-4AE0-99E6-A48A6586A445Q42725709-C2FE981B-7545-4F2D-8920-DEAFD869E0D8Q42961795-F6F54F83-66C6-4B6F-9074-5E26961192FCQ51297212-5F3A492C-42CB-4E1A-BED8-168E986ED523
P2860
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@ast
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@en
type
label
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@ast
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@en
prefLabel
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@ast
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@en
P2093
P2860
P50
P356
P1476
Phase II studies of gemcitabin ...... ated metastatic breast cancer.
@en
P2093
Alexander Hantel
Christy Russell
Darcy Spicer
George Somlo
Helen K Chew
James H Doroshow
Kathy S Albain
Kim A Margolin
Merry L Tetef
Michael Gordon
P2860
P304
P356
10.1200/JCO.2008.17.4839
P407
P577
2009-03-23T00:00:00Z